利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.024 秒)

    Radiosensitizer
    1.
    发明申请
    Radiosensitizer 审中-公开
    放射增敏剂

    公开(公告)号：US20060217291A1

    公开(公告)日：2006-09-28

    申请号：US11337557

    申请日：2006-01-24

    申请人： Ichiro Hirotsu ,  Yuki Ohkawa ,  Hisashi Yamamoto ,  Makoto Sato ,  Koichi Kobayashi ,  Hirohisa Horinouchi

    发明人： Ichiro Hirotsu ,  Yuki Ohkawa ,  Hisashi Yamamoto ,  Makoto Sato ,  Koichi Kobayashi ,  Hirohisa Horinouchi

    IPC分类号： A61K38/36 ,  A61K31/737 ,  A61K31/555 ,  C07D487/22

    CPC分类号： A61K31/409 ,  A61K41/0038

    摘要： There is provided a radiosensitizer containing an iron compound, more specifically, a radiosensitizer containing an iron compound selected from an inorganoiron compound, such as iron chloride, iron oxide, iron hydroxide, and iron sulfate; and an organoiron compound, such as saccharated ferric oxide, iron citrate, iron gluconate, chondroitin sulfate/iron colloid, cideferron, ferrotrenine, iron fumarate, iron pyrophosphate, a porphyrin-iron complex, and an albumin incorporating porphyrin-iron complex.

    摘要翻译： 提供了含有铁化合物的放射增敏剂，更具体地，含有选自无机铁化合物如氯化铁，氧化铁，氢氧化铁和硫酸铁中的铁化合物的放射增敏剂; 以及有机铁化合物，例如糖化氧化铁，柠檬酸铁，葡萄糖酸铁，硫酸软骨素/铁胶体，西德弗龙，铁铁蛋白，富马酸铁，焦磷酸铁，卟啉 - 铁络合物和掺入卟啉 - 铁络合物的白蛋白。

    Agent for improving circulatory disorder
    2.
    发明申请
    Agent for improving circulatory disorder 审中-公开
    改善循环障碍的药物

    公开(公告)号：US20090275732A1

    公开(公告)日：2009-11-05

    申请号：US11920145

    申请日：2006-04-27

    申请人： Ichiro Hirotsu ,  Yuki Ohkawa ,  Masanori Nozako ,  Saori Suzuki ,  Yukiko Kuwata ,  Makoto Sato

    发明人： Ichiro Hirotsu ,  Yuki Ohkawa ,  Masanori Nozako ,  Saori Suzuki ,  Yukiko Kuwata ,  Makoto Sato

    IPC分类号： C07K14/765 ,  C07K14/76

    CPC分类号： A61K9/0019 ,  A61K31/409 ,  A61K31/7135

    摘要： Provided is a pharmaceutical agent capable of efficiently improving blood circulation in a region where a circulatory disorder occurs and fully preventing or improving tissue damage as a preventive or therapeutic agent for circulatory disorders in general. As a result of the study of pharmacological effects of a compound in which a porphyrin metal complex is clathrated in albumin, it was found that the compound efficiently improves decreases in blood flow in circulatory disorders and fully prevents or improves tissue damage, thus the invention was achieved. That is, the invention is directed to an agent for improving a circulatory disorder including a compound in which a porphyrin metal complex is clathrated in albumin.

    摘要翻译： 本发明提供能够有效改善发生循环障碍的区域的血液循环的药剂，并且作为循环障碍的预防或治疗剂，充分地防止或改善组织损伤。 研究了其中卟啉金属络合物在白蛋白中包合的化合物的药理作用的结果，发现该化合物有效地改善了循环障碍中血流量的降低，并且完全防止或改善了组织损伤，因此本发明是 实现了 也就是说，本发明涉及用于改善循环障碍的药剂，包括其中卟啉金属络合物在白蛋白中包合的化合物。

    Benzoxazepine derivatives and their salts and medicaments containing the same
    4.
    发明授权
    Benzoxazepine derivatives and their salts and medicaments containing the same 有权
    苯并西泮衍生物及其盐及含有它们的药物

    公开(公告)号：US06187769B1

    公开(公告)日：2001-02-13

    申请号：US09306995

    申请日：1999-05-07

    申请人： Toshio Tatsuoka ,  Katsuhide Kamei ,  Noriko Maeda ,  Teruyoshi Inoue ,  Mika Nakajima ,  Ichiro Hirotsu

    发明人： Toshio Tatsuoka ,  Katsuhide Kamei ,  Noriko Maeda ,  Teruyoshi Inoue ,  Mika Nakajima ,  Ichiro Hirotsu

    IPC分类号： C07D40114

    CPC分类号： C07D401/04 ,  C07D267/14 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14

    摘要： A benzoxazepine derivative having the general formula (I) and its salts and medicaments containing the same as effective ingredients: wherein, n is an integer of 2 to 5, R1 indicates a hydrogen atom, halogen atom, C1 to C4 lower alkyl group, C1 to C4 lower alkoxyalkyl group, C1 to C4 halogenoalkyl group, cyano group, or ester group, R2 indicates a hydrogen atom, halogen atom, C1 to C4 lower alkyl group, C1 to C4 lower alkoxy group, or hydroxy group, a dotted line indicates the presence or absence of a binding bond, W indicates C, CH, or CH2 or a nitrogen atom, provided that, when W is a nitrogen atom, Z is bonded to W and the dotted line indicates the absence of a bond, and Z indicates an unsubstituted or substituted aromatic hydrocarbon ring group or an unsubstituted or substituted heterocyclic group). This benzoxazepine derivative and its salts are useful as medicaments for the treatment of anxiety neurosis, phobias, obsessive-compulsive disorders, schizophrenia, post-cardiac trauma stress, depression, psychosomatic and other psychoneurotic disorders, eating disorders, menopausal disorders, infantile autism and also emesis or disorders involving the cerebral circulatory system accompanying cerebral infarction and cerebral hemorrhage.

    摘要翻译： 具有通式（I）的苯并氧氮杂衍生物及其盐和药物含有效成分：其中n为2〜5的整数，R1表示氢原子，卤素原子，C1〜C4低级烷基，C1 C4低级烷氧基烷基，C1〜C4卤代烷基，氰基或酯基，R2表示氢原子，卤素原子，C1〜C4低级烷基，C1〜C4低级烷氧基或羟基，虚线表示 存在或不存在结合键，W表示C，CH或CH 2或氮原子，条件是当W为氮原子时，Z与W键合，虚线表示不存在键，并且Z 表示未取代或取代的芳族烃环基团或未取代或取代的杂环基团）。该苯并氧氮杂衍生物及其盐可用作治疗焦虑性神经症，恐怖症，强迫症，精神分裂症，心脏外伤后的药物 精神分裂症，抑郁症，心身和其他精神神经性疾病，进食障碍，绝经障碍，婴儿自闭症以及涉及脑梗死和脑出血的脑循环系统的呕吐或紊乱。